Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-11-03
2011-11-08
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006140, C435S006170, C435S006180, C536S023500, C536S024100
Reexamination Certificate
active
08053189
ABSTRACT:
The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention.
REFERENCES:
patent: 2004/0053304 (2004-03-01), Markowitz
patent: 2009/0111120 (2009-04-01), Meltzer et al.
patent: 2009/0215709 (2009-08-01), Van Criekinge et al.
patent: 2004086949 (2004-10-01), None
patent: 2005001140 (2005-01-01), None
patent: 2005003381 (2005-01-01), None
patent: 2006002344 (2006-01-01), None
patent: WO 2006/088940 (2006-08-01), None
Ehrlich et al. Oncogene 2002. 21: 5400-5413.
Ushijima et al. Nature Reviews. 2005. 5: 223-231.
Tang et al. International Journal of Cancer. 2006. 119: 2603-2606; published online Sep. 21, 2006.
Goel et al. Gastroenterology. Jan. 2007. 132(1): 127-138.
Wojdacz et al. Nucleic Acids Research. Feb. 2007. 35: e41, pp. 1-7.
Ogino et al. Gut 2006. 55: 1000-1006.
Konstanze Lenhard, et al., “Analysis of Promoter Methylation in Stool: A Novel Method for the Detection of Colorectal Cancer”, Clinical Gastroentrology and Hepatology, 2005, vol. 3, pp. 142-149.
David A. Ahlquist, et al., “Colorectal Cancer Screening by Detection of Altered Human DNA in Stool: Feasibility of a Multitarget Assay Pane”, Gastroebterology, 2000, vol. 119, pp. 1219-1227.
David A. Ahlquist, “Stool-Based DNA Tests for Colorectal Cancer: Clinical Potential and Early Results”, Reviews in Gastroenterological Disorders, 2002, vol. 2, pp. s20-s26.
David A. Ahlquist, et al., “Stool screening for colorectal cancer: evolution from occult blood to molecular markers”, Clinica Chimica Acta 315, 2002, pp. 157-168.
Nigel J.Belshaw, et al., Use of DNA from Human Stools to Detect Aberrant CpG Island Methylation of Genes Implicated in Colorectal Cancer?, Cancer Epidemiol Biomarkers Prev, 2004, vol. 13, No. 9. pp. 1495-1501.
Dean E. Brenner, et al., “Fecal DNA Biomarkers for the detection of Colorectal Neoplasia: Attractive but Is IT Feasible”, Journal of the National Cancer Institute, vol. 97, No. 15, Aug. 3, 2005, pp. 1107-1109.
Gabriel Capella, “Is fecal DNA testing superior to fecal occult-blood testing for colorectal cancer screening?” Nature Clinical Practice, May 2005, vol. 2, No. 5, pp. 234-235.
Seung Myung Dong, et al., “Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets”, Journal of the National Cancer Institute, Jun. 2001, vol. 93, No. 11, pp. 858-865.
Susumu Eguchi, et al., “Mutations of the P53 Gene in the Stool of Patients with Resectable Colorectal Cancer”, Presented at the Seventh Annual Meeting of the Japanese Research Society for Gastroenterological Carcinogensis, Oita, Japan, Sep. 8-9, 1995.
James G. Herman, et al., “Methylation-specific PCR: A novel PCR assay for methylation status of CPG islands”, Proc. Natl. Acad. Sci. USA, vol. 93. pp. 9821-9826, Sep. 1996.
Manel Esteller. et al., “Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome”, Onogene, 2000, vol. 19, pp. 164-168.
Manel Esteller, “Epigenetics in Cancer”, New England Journal of Medicine, 2008, vo. 358, pp. 1148-1159.
Manel Esteller, et al., “A Gene Hypermethylation Profile of Human Cancer”, Perspectives in Cancer Research, vol. 61, pp. 3225-3229,Apr. 15, 2001.
Manel Esteller, et al., Analysis of Adenomatous Polyposis Coli Promoter Hypermethylation in Human Cancer, Cancer Research 60, pp. 4366-4371, Aug. 15, 2001.
Manel Esteller, et al., “DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis”, Human Molecular Genetics, 2001, vol. 10, No. 26, pp. 3001-3007.
Manel Esteller, et al., “Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer”, Cancer Research 62, Oct. 15, 2002, pp. 5902-5905.
Jordi Frigola, et al., “Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across and entire chromosome band”, Nature Genetics, vol. 38, No. 5, May 2006, pp. 540-549.
James G. Herman, et al., “Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma”, Proc. Natl. Acad. Sci. USA, vol. 95. pp. 6870-6875, Jun. 1998.
Helen M. Sheilds, et al., “Factors That Influence the Decision to Do an Adequate Evaluation of a Patient with a Positive Stool for Occult Blood”, The American Journal of Gastroenterology, vol. 96, No. 1, 2001, pp. 196-201.
Kenneth Song, et al, “Fecal DNA Testing Compared With Conventional Colorectal Cancer Screening Methods: A Decision Analysis”, Gastroenterology 2004, vol. 126, pp. 1270-1279.
Giovanni Traverso, et al., “Detection of APC Mutations in Fecal DNA From Patients With Colorectal Tumors”, New England Journal of Medicine, vol. 346, No. 5, pp. 311-320.
Giovanni Traverso, et al., “Detection of proximal colorectal cancers through analysis of faecal DNA”, The Lancet, vol. 359, (2002), pp. 403-404.
Duncan Whitney, et al., “Enhanced Retrieval of DNA from Human Fecal Samples in Improved Performance of Colorectal Cancer Screening Test”, Journal of Molecular Diagnostics, vol. 6, No. 4, Nov. 2004, pp. 386-395.
Sidney Winawer, et al. “Colorectal Cancer Screening and Surveillance: Clinical Guidelines and Rational-Update Based on New Evidence”, American Gastroenterological Association Gastroenterology, 2003, vol. 124, pp. 544-560.
Hong Zou, et al, “Highly Methylated Genes in Colorectal Neoplasia: Implications for Screening”, Cancer Epidemiol Biomarkers Prev., Dec. 2007, vol. 16, No. 12. pp. 2686-2696.
Marion Zitt, et al., “DNA methylation in colorectal cancer-Impact on screening and therapy monitoring modalities?”, Disease Markers 23, (2007) pp. 51-71.
Hong-Zhi Zou, et al., “Detection of Aberrant p16 Methylaytion in the Serum of Colorectal Cancer Patients”, Clinical Cancer Research, vol. 8, Jan. 2002, pp. 188-191.
Hannes M. Muller, “Methylation changes in faecal DNA: a marker for colorectal cancer screening”, The Lancet, vol. 363, Apr. 17, 2004, pp. 1283-1285.
Thomas F. Imperiale, et al., “Risk of Advanced Proximal Neoplasms in Asymptomatic Adults According to The Distal Colorctal Findings”, The New England Journal of Medicine, vol. 343, No. 3, Jul. 2000, pp. 169-174.
Thomas F. Imperiale, et al., “Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population”, New England Journal of Medicine, vol. 351, No. 26, Dec. 23, 2004, pp. 2704-2714.
Lasse S. Kristensen, et al., “Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection”, Nucleic Acids Research, 2008, vol. 36, No. 7.
Wai K. Leung, et al., “Detection of Hypermethylated DNA or Cyclooxygenase-2 Messanger RNA in Fecal Samples of Patients with Colorectal Cancer or Polyps”, American Journal of Gastroenterology, 2007, vol. 102, pp. 1070-1076.
Wai K. Leung, et al., “Quantitative Detection of Promoter Hypermethylation in Multiple Genesd in the Serum of Patients with Colorectal Cancer”, American Journal of Gastroenterology, 2005, vol. 100, pp. 2274-2279.
Wai K. Leung, et al., “Detection of Epigenetic Changes in Fecal DNA as a Molecular Screening for Colorectal Cancer: A Feasible Study”, Clinical Chemistry 50, No. 11, 2004, pp. 2179-2182.
David A. Lieberman, et al., “Use of Colonoscopy to Screen Asymptomatic Adults for Colorectal Cancer”, The New England Journal of Medicine, vol. 343, No. 3, Jul. 20, 2000, pp. 162-168.
Alexandre Loktionov, et al., “Quantitation of DNA from Exfoliated Colonocytes Isolat
García Daniel Azuara
Munar Gabriel Capella
Cantor & Colburn LLP
Fina Biotech, S.L.U.
Myers Carla
LandOfFree
Method for the diagnosis of colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the diagnosis of colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the diagnosis of colorectal cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286146